New drug shows promise for hard-to-treat cancers with HER2 mutations
NCT ID NCT04639219
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with advanced solid tumors that have certain HER2 gene mutations and have stopped responding to other treatments. The goal is to see if the drug can shrink tumors. About 102 adults with various cancer types (like colorectal, bladder, stomach, or ovarian) are taking part. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Santa Rosa, California, 95403, United States
-
Research Site
Muncie, Indiana, 47303, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Middletown, New Jersey, 07748, United States
-
Research Site
Commack, New York, 11725, United States
-
Research Site
Harrison, New York, 10604, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Anderlecht, 1070, Belgium
-
Research Site
Toronto, CA, M5G 2M9, Canada
-
Research Site
Copenhagen, 2100, Denmark
-
Research Site
Bordeaux, 33076, France
-
Research Site
Lyon, 69008, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Milan, 20141, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Suita-shi, 565-0871, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Seville, 41013, Spain
Conditions
Explore the condition pages connected to this study.